| Literature DB >> 35035914 |
Mathilde Kersting1, Hermann Kalhoff1,2, Bernd Honermeier3, Kathrin Sinningen1, Thomas Lücke1.
Abstract
Recently, the European Food Safety Authority (EFSA) issued a tolerable daily intake (TDI) for erucic acid, which is mainly found in rapeseed oil. Infants may be exposed to erucic acid from rapeseed oil indirectly through maternal consumption via breastmilk or the fat component in formula, and directly as a part of complementary feeding (CF). To check the safety of infant nutrition, scenarios for erucic acid exposure were calculated based on the daily food amounts of the German dietary guidelines. Information on erucic acid concentrations in foods was obtained from European studies for breastmilk, from EFSA samples for formula powder, and from a representative analysis of rapeseed oil samples in the German retail market. 6 scenarios were calculated for the early milk feeding phase (4 formula feeding, 2 breastfeeding) and 8 scenarios for the later CF phase (5 CF +formula feeding, 3 CF +breastfeeding). Out of the 14 scenarios, only 3 resulted in exposures that were definitively below the TDI (range 4.4.-6.0 mg/kg bodyweight; BW). Assuming either high consumption or high concentration led to high exceedances (range 7.5-26.2 mg/kg BW), especially in case of the new EU limits for formula or vegetable oils (33.6 and 43.2 mg/kg BW, respectively). In our scenarios, high erucic acid exposures occurred during a particularly sensitive developmental period. To definitively weigh the potential risks from erucic acid in infants against nutritional benefits of the dietary recommendations, reliable, timely data on erucic acid in breast milk and formula are needed, similar to those from rapeseed oil in Germany.Entities:
Keywords: exposure scenarios; food contaminants; infant nutrition; rapeseed oil; total daily diet
Year: 2021 PMID: 35035914 PMCID: PMC8751447 DOI: 10.1002/fsn3.2652
Source DB: PubMed Journal: Food Sci Nutr ISSN: 2048-7177 Impact factor: 2.863
FIGURE 1Dietary scheme for the first year of life
Dietary Scheme for the first year of life—Recipes of the three daily complementary meals at the age of about 8 months
| First meal | Second meal | Third meal | |||
|---|---|---|---|---|---|
| Home prepared | |||||
| Vegetable–potato‐–meat–meal | Milk–cereal–meal | Cereal–fruit–meal | |||
| 100 g | Vegetables | 200 g | Milk | 20 g | Cereals |
| 50 g | Potatoes | 20 g | Cereals | 90 g | Water |
| 30 g | Meat/Fish | 20 g | Juice/Fruit | 100 g | Fruit |
| 5 g | Rapeseed oil | 5 g | Rapeseed oil | ||
Scenarios for exclusive milk feeding (formula or breastmilk [BM])
| TDI: Erucic acid 7 mg/kg BW | |||
|---|---|---|---|
| A1: Formula | Selected data sources | Data values | Exposure: Erucic acid mg/kg BW |
| 1 | Consumption p50 × 12% powder in 100 g formula x MB concentration (EFSA samples infant formula powder) | 0.199 kg/kg × 0.12 × 253 (mg/kg) | 6.04 mg/kg |
| 2 | Consumption p95 × 12% powder in 100 g formula x MB concentration (EFSA samples infant formula powder) | 0.257 kg/kg × 0.12 × 253 (mg/kg) | 7.80 mg/kg |
| 3 | Consumption p50; EU maximum level for fat in 100 g formula (4,200 mg) x EU permitted maximum concentration of erucic acid in fat (0.4%) | 0.199 kg/kg × (4,200 mg/0.1 kg) × 0.004 | 33.6 mg/kg |
| 4 | Consumption p95; EU maximum level for fat in 100 g formula (4,200 mg) x EU permitted maximum concentration of erucic acid in fat (0.4%) | 0.257 kg/kg × (4,200 mg/0.1 kg) × 0.004 | 43.2 mg/kg |
| A2: BM | |||
| 1 | Consumption p50 estimated (formula p50—10%); concentration (European studies) | 0.179 kg/ /kg × (0.001 × 42,000 mg/kg) | 7.52 mg/kg |
| 2 | Consumption p95 estimated (formula p95—10%); concentration (European studies) | 0.231 kg/kg × (0.001 × 42,000 mg/kg) | 9.70 mg/kg |
Scenarios for complementary feeding (CF) + milk (Formula, Breastmilk [BM])
| Selected data sources | Data values | TDI: Erucic acid 7 mg/kg BW | ||
|---|---|---|---|---|
| B1: CF+Formula | Rapeseed oil (p50: 2.67 g/kg) (p95: 6.06 g/kg) + formula | Exposure total | Exposure/kg BW | |
| 1 | 10 g rapeseed oil; p50 German samples; + follow‐on formula 200 mL (EU samples) | 26.7 mg + 200 mL × 0.03 (mg/mL) | 32.7 | 4.14 |
| 2 | 10 g rapeseed oil; p50 German samples:; + follow‐on formula 200 mL (EU permitted maximum) | 26.7 mg + 200 mL × 0.167 (mg/mL) | 60.1 | 7.61 |
| 3 | 10 g rapeseed oil; p95 German samples; + follow‐on formula 200 mL (EU samples) | 60.1 mg + 200 mL × 0.03 (mg/mL) | 66.1 | 8.37 |
| 4 | 10 g rapeseed oil; p95 German samples; + follow‐on formula 200 mL (EU permitted maximum) | 60.1 mg + 200 mL × 0.167 (mg/mL) | 93.5 | 11.8 |
| 5 | 10 g rapeseed oil (max. proposed level EU) + follow‐on formula 20 mL (EU permitted maximum) | 200 mg + 200 mL × 0.167 (mg/mL) | 233.4 | 29.5 |
| B2: CF +BM | ||||
| 1 | 10 g rapeseed oil; p50 German samples; + BM 200 mL (European studies) | 26.7 mg + 200 mL × (0.001 × 42 mg/mL) | 35.1 | 4.44 |
| 2 | 10 g rapeseed oil; p95 German samples +BM 200 mL (European studies) | 60.1 mg + 200 mL × (0.001 × 42 mg/mL) | 68.5 | 8.7 |
| 3 | 10 g rapeseed oil; proposed EU maximum; + BM 200 mL (European studies) | 200 mg + 200 mL × (0.001 × 42 mg/mL) | 208.4 | 26.4 |
FIGURE 2Overview of the results of 14 exposure scenarios in comparison with the TDI